Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2020 Earnings Conference Call November 23, 2020 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration and CFO Conference Call Participants Roy Buchanan - JMP Securities Yasmeen Rahimi - Piper Sandler Eric Joseph - JP Morgan Jay Olson - Oppenheimer Operator Good afternoon and welcome to Enanta Pharmaceuticals fiscal fourth quarter and year-e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 2834 (Primary Standard Industrial Classification Code Number) DELAWARE 04-3205099 (S ...

Corporate Presentation August 4, 2020 ENANTA Pharmaceuticals 1 © 2020 | 1 Pl Creating Small Molecule Drugs for Viral Infections and Liver Diseases Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not stateme ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2020 Earnings Conference Call August 4, 2020 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration and CFO Conference Call Participants Eric Joseph - JPMorgan Chase & Co. Brian Skorney - Robert W. Baird & Co. Douglas Buchanan - JMP Securities Leonid Timashev - RBC Capital Markets Jay Olson - Oppenheimer Amy Li - Wolfe Research Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 2834 (Primary Standard Industrial Classification Code Number) DELAWARE 04-3205099 ( ...

From Chemistry to Cures ENANTA Pharmaceuticals 1 A Phase 2 dose ranging, randomized, double-blind and placebo-controlled study of EDP-305 in subjects with primary biliary cholangitis (PBC) with or without an inadequate response to ursodeoxycholic acid (UDCA) Topline Results 06MAY2020 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our plans, objectives and expectations for EDP-305 and its development for NASH. Any statements contained herein that are no ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR Jay Luly - President & CEO Paul Mellett - CFO Nathalie Adda - SVP & CMO Conference Call Participants Yasmeen Rahimi - Roth Capital Partners Akash Tewari - Wolfe Research Operator Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Second Quarter Financial Results Conference Call. [Operator Instructions] There will be a question-and-answer sessi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 2834 (Primary Standard Industrial Classification Code Number) DELAWARE 04-320509 ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2020 Results Conference Call February 6, 2020 4:30 PM ET Company Participants Carol Miceli - Director, IR Dr. Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - SVP and CMO Conference Call Participants Brian Abrahams - RBC Eric Joseph - JP Morgan Akash Tewari - Wolfe Research Liisa Bayko - JMP Securities Brian Skorney - Baird Iris Long - Berenberg Capital Management Operator Ladies and gentlemen, thank you for standing by, and welcome to the Enanta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 | --- | --- | --- | |-----------------------------------------|-----------------------------------------------------------------|------------------------------------------ ...